tetano
Editor, Senior Moderator
Arthritis Care Res (Hoboken). 2011 Mar 18. doi: 10.1002/acr.20465. [Epub ahead of print]
The efficacy and safety of vaccination against pandemic 2009 influenza a (H1N1) virus among patients with rheumatic diseases.
Ori E, Sharon A, Ella M, Mitchell S, Itamar G, Jonathan W, Uri A, Ayelet B, Daphna P, David L, Irena W, Dan C, Michal M.
Department of Rheumatology, Tel Aviv Medical Center, both affiliated to the "Sackler" Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. oribe14@netvision.net.il.
Abstract
OBJECTIVE: To assess the efficacy and safety of vaccination against pandemic H1N1 virus in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) compared with healthy controls.
METHODS: The study population comprised 41 RA patients, 21 SLE patients, 17 PsA patients, 15 AS patients, and 25 healthy controls, all vaccinated using the Novartis MF59-adjuvanted H1N1v monovalent influenza vaccine. The immunogenicity of the vaccine was assessed on day 1 and again 4 weeks later by hemagglutination inhibition assay. Geometric mean titers (GMTs) and seroconversion rates were calculated for each group. The safety of the vaccine was evaluated using the disease activity score (DAS) for RA and PsA, the Systemic Lupus Disease Activity Index (SLEDAI), and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
RESULTS: The proportion of baseline protective levels of antibodies against H1N1 was similar in all but the AS group in which it was lower. The GMT increased significantly in all 5 groups. A substantial proportion of patients and controls responded to the vaccine. The healthy controls demonstrated a better response than each of the other groups: 82% vs 56% for RA, 67% for SLE, 59% for PsA and 53% for AS. Multivariate logistic regression analysis identified RA and PsA as parameters of significantly lower response. The DAS, BASDAI and SLEDAI remained unchanged after vaccination
CONCLUSIONS: Vaccination against pandemic H1N1 using an adjuvanted H1N1v monovalent influenza is safe and induced an appropriate response in patients with RA, SLE, PsA and AS.
Copyright ? 2011 by the American College of Rheumatology.
PMID: 21425247 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21425247
The efficacy and safety of vaccination against pandemic 2009 influenza a (H1N1) virus among patients with rheumatic diseases.
Ori E, Sharon A, Ella M, Mitchell S, Itamar G, Jonathan W, Uri A, Ayelet B, Daphna P, David L, Irena W, Dan C, Michal M.
Department of Rheumatology, Tel Aviv Medical Center, both affiliated to the "Sackler" Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. oribe14@netvision.net.il.
Abstract
OBJECTIVE: To assess the efficacy and safety of vaccination against pandemic H1N1 virus in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) compared with healthy controls.
METHODS: The study population comprised 41 RA patients, 21 SLE patients, 17 PsA patients, 15 AS patients, and 25 healthy controls, all vaccinated using the Novartis MF59-adjuvanted H1N1v monovalent influenza vaccine. The immunogenicity of the vaccine was assessed on day 1 and again 4 weeks later by hemagglutination inhibition assay. Geometric mean titers (GMTs) and seroconversion rates were calculated for each group. The safety of the vaccine was evaluated using the disease activity score (DAS) for RA and PsA, the Systemic Lupus Disease Activity Index (SLEDAI), and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
RESULTS: The proportion of baseline protective levels of antibodies against H1N1 was similar in all but the AS group in which it was lower. The GMT increased significantly in all 5 groups. A substantial proportion of patients and controls responded to the vaccine. The healthy controls demonstrated a better response than each of the other groups: 82% vs 56% for RA, 67% for SLE, 59% for PsA and 53% for AS. Multivariate logistic regression analysis identified RA and PsA as parameters of significantly lower response. The DAS, BASDAI and SLEDAI remained unchanged after vaccination
CONCLUSIONS: Vaccination against pandemic H1N1 using an adjuvanted H1N1v monovalent influenza is safe and induced an appropriate response in patients with RA, SLE, PsA and AS.
Copyright ? 2011 by the American College of Rheumatology.
PMID: 21425247 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21425247